Biotech | April 09, 2026
Gilead to acquire Tubulis for up to $5 billion to strengthen its oncology portfolio
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge
The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
The approval comes after a systematic review of published literature
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
Subscribe To Our Newsletter & Stay Updated
